Isolation of hyperactive mutants of mammalian target of rapamycin.
about
mTOR kinase structure, mechanism and regulationActivating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolutionTGFβ-stimulated microRNA-21 utilizes PTEN to orchestrate AKT/mTORC1 signaling for mesangial cell hypertrophy and matrix expansionGenetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysisSomatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.Activating mutations in TOR are in similar structures as oncogenic mutations in PI3KCalpha.Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer.microRNA-21-induced dissociation of PDCD4 from rictor contributes to Akt-IKKβ-mTORC1 axis to regulate renal cancer cell invasion.microRNA-21 governs TORC1 activation in renal cancer cell proliferation and invasionGenetic variations in a PTEN/AKT/mTOR axis and prostate cancer risk in a Chinese population.Activating mutations of TOR (target of rapamycin).Reassessment of the role of TSC, mTORC1 and microRNAs in amino acids-meditated translational control of TOP mRNAs.Target of rapamycin (TOR) in nutrient signaling and growth controlUnrestrained mammalian target of rapamycin complexes 1 and 2 increase expression of phosphatase and tensin homolog deleted on chromosome 10 to regulate phosphorylation of Akt kinase.Germline activating MTOR mutation arising through gonadal mosaicism in two brothers with megalencephaly and neurodevelopmental abnormalitiesThe Transcription Factor Bach2 Is Phosphorylated at Multiple Sites in Murine B Cells but a Single Site Prevents Its Nuclear Localization.Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.Mutations in critical domains confer the human mTOR gene strong tumorigenicity.MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.Association of maternal mRNA and phosphorylated EIF4EBP1 variants with the spindle in mouse oocytes: localized translational control supporting female meiosis in mammals.mTOR pathway in colorectal cancer: an update.Mammalian TOR signaling to the AGC kinases.Targeting the PI3K/Akt/mTOR pathway in malignancy: rationale and clinical outlook.mTOR signaling and its roles in normal and abnormal brain development.Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer.Hyperactive mTOR induces neuroendocrine differentiation in prostate cancer cell with concurrent up-regulation of IRF1.Reciprocal regulation of miR-214 and PTEN by high glucose regulates renal glomerular mesangial and proximal tubular epithelial cell hypertrophy and matrix expansion.Mechanisms of mTORC1 activation by RHEB and inhibition by PRAS40.An In Vitro TORC1 Kinase Assay That Recapitulates the Gtr-Independent Glutamine-Responsive TORC1 Activation Mechanism on Yeast Vacuoles.
P2860
Q27677954-9D18977C-F8AB-42E0-B8CD-A472161B1B69Q27852954-8482A7FF-717C-45E9-8991-9A235656B597Q28655705-516EA9DE-6A25-4B39-934C-F53F88068781Q28975741-BEC5E90A-6EBF-4C5A-8FB5-8CD50298162CQ29248629-4E874655-2657-433A-ABED-5B752CF05C85Q30274622-C3874B5A-2646-4073-BD62-9003F4F449C7Q30437618-798785FB-1A0F-4830-A10A-0A1A09E745DEQ34101115-5CC5706E-13F1-4EE2-BBD4-8E7682259618Q34257789-8EDB10E1-13D5-46CE-9C77-E48A24A7A68EQ34299534-2B297A07-86C4-428A-B28E-BBC4B6D2246EQ34345248-AD605545-6F35-4253-BE34-687F28056D3DQ35049778-44760C45-AF77-4A76-83F3-F93540AB8BE2Q35358625-58E521CA-20D8-495C-AE8D-9F5C31060DBEQ35620394-230FAD59-A553-4A6E-9543-F4E0EFEA9933Q35763142-C6ACF3E9-BD9F-41D9-9975-C6616B73E9BCQ35834127-9CC8ED4F-7E1D-4181-9764-B92F454E500FQ36489294-56F3705C-1417-40E5-9E80-AC0F32979A44Q36535062-DFB82564-AF3B-4E90-B3E4-650AACF1150CQ36647365-C4D7DCC1-70A1-4E99-97A9-F1518607B465Q37078685-1A4D13D7-03B0-43AC-9116-7711A765EDA8Q37194747-3DFA6498-8A83-4AB5-952F-948DA56574ECQ37649634-43C583DB-9BAF-43EC-A8FC-FE8BC18903ECQ37943416-24E3885D-2470-4DD3-913C-D070AD37FA9CQ38190918-4B91BAD9-E9CF-487D-8478-CDF76CE12774Q38209310-10C4A79B-F350-4F9E-898D-813ACBF9F40BQ39590044-3F7C4C7D-3795-4DE8-AF45-13CC62913343Q40472184-4430B8AE-7292-4F75-848B-5CA6A135176EQ47805023-835B3D55-B06E-4D51-845A-9092101C8CA6Q47828965-FCE21FDA-B3C1-4439-903E-EE98F787E75FQ47918070-FE30DBF7-F108-48FF-898B-6741E92C61FEQ49751490-C4B424CB-B22C-40BA-8C4F-9456DB79A4C1
P2860
Isolation of hyperactive mutants of mammalian target of rapamycin.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Isolation of hyperactive mutants of mammalian target of rapamycin.
@en
Isolation of hyperactive mutants of mammalian target of rapamycin.
@nl
type
label
Isolation of hyperactive mutants of mammalian target of rapamycin.
@en
Isolation of hyperactive mutants of mammalian target of rapamycin.
@nl
prefLabel
Isolation of hyperactive mutants of mammalian target of rapamycin.
@en
Isolation of hyperactive mutants of mammalian target of rapamycin.
@nl
P2093
P2860
P356
P1476
Isolation of hyperactive mutants of mammalian target of rapamycin.
@en
P2093
Makoto Noda
Riko Hatakeyama
Tatsuya Maeda
Terunao Takahara
Tomoko Matsuzaki
Yoichiro Ohne
P2860
P304
31861-31870
P356
10.1074/JBC.M801546200
P407
P577
2008-09-23T00:00:00Z